DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2006-05-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00262-006-0170-6PMID 16676183PMCID PMC11030744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

  2005cited by this paper
• Autologous peptides eluted from acute myeloid leukemia cells can be used to generate specific antileukemic CD4 helper and CD8 cytotoxic T lymphocyte responses in vitro.

  2005cited by this paper
• Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA.

  2005influential reference
• Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells1

  2005cited by this paper
• Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.

  2005cited by this paper
• Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease

  2005cited by this paper
• Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.

  2004cited by this paper
• Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

  2004cited by this paper
• Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection 1

  2004cited by this paper
• mRNA expression of leukemia‐associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies

  2004cited by this paper
• Therapeutic Effect of Dendritic Cells Loaded with a Fusion mRNA Encoding Tyrosinase-Related Protein 2 and Enhanced Green Fluorescence Protein on B16 Melanoma

  2004influential reference
• Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo

  2004cited by this paper
• A Novel System for Simultaneous in Vivo Tracking and Biological Assessment of Leukemia Cells and ex Vivo Generated Leukemia-Reactive Cytotoxic T Cells

  2004cited by this paper
• Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses

  2004cited by this paper
• Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell–based cancer vaccination

  2004cited by this paper
• Immunotherapy of hematologic malignancy.

  2003cited by this paper
• Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules1

  2003cited by this paper
• Generation of tumor cell lysate-loaded dendritic cells preprogrammed for IL-12 production and augmented T cell response

  2003cited by this paper
• Multiple pathways to tumor immunity and concomitant autoimmunity

  2002cited by this paper
• Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell–leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination

  2002cited by this paper
• Equipotent Generation of Protective Antitumor Immunity by Various Methods of Dendritic Cell Loading With Whole Cell Tumor Antigens.

  2001cited by this paper
• Equipotent Generation of Protective Antitumor Immunity by Various Methods of Dendritic Cell Loading With Whole Cell Tumor Antigens

  2001cited by this paper
• Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.

  2001cited by this paper
• HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse

  2001cited by this paper
• Induction and clonal expansion of tumor‐specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells

  2001cited by this paper
• Induction of Ovarian Tumor‐Specific CD8+ Cytotoxic T Lymphocytes by Acid‐Eluted Peptide‐Pulsed Autologous Dendritic Cells

  2000cited by this paper
• Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.

  2000cited by this paper
• Simultaneous expression of different immunogenic antigens in acute myeloid leukemia.

  2000cited by this paper
• Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.

  2000cited by this paper
• Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.

  2000cited by this paper
• Cancer immunotherapy: synthetic and natural peptides in the balance.

  1999cited by this paper
• Murine dendritic cells transfected with human GP100 elicit both antigen‐specific CD8+ and CD4+ T‐cell responses and are more effective than DNA vaccines at generating anti‐tumor immunity

  1999cited by this paper
• Antileukemic HLA-restricted T-cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts.

  1998cited by this paper
• Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes

  1998cited by this paper
• Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

  1996cited by this paper
• Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

  1996cited by this paper
• Do human cancers express shared protective antigens? or the necessity of remembrance of things past.

  1996cited by this paper
• Dependency on intercellular adhesion molecule recognition and local interleukin-2 provision in generation of an in vivo CD8+ T-cell immune response to murine myeloid leukemia.

  1995cited by this paper
• In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen‐presenting cells

  1994cited by this paper
• Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution.

  1993cited by this paper
• Identification of T-cell epitopes.

  1993cited by this paper
• Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast

  1991cited by this paper
• Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y.

  1990cited by this paper
• Diagnostic and prognostic significance of myelomonocytic cell surface antigens in acute myeloid leukaemia

  1989cited by this paper
• In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones.

  1988cited by this paper
• Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.

  1985cited by this paper
• Establishment and characterization of BALB/c lymphoma lines with B cell properties.

  1979cited by this paper
• Myeloid leukemia C-1498 as a screen for cancer chemotherapeutic agents.

  1966cited by this paper

• A New Strategy to Identify Naturally Presenting SLA-I Bound Peptides Derived from the O Serotype of Foot-and-Mouth Disease Virus, by Mild Acid Elution in a VP1 Stably Expressed PK15 Cell Line

  2025cites this paper
• Dosage and organic acid residue of myelin oligodendrocyte glycoprotein35–55 peptide influences immunopathology and development of Bacillus Calmette-Guérin induced experimental autoimmune encephalomyelitis

  2024cites this paper
• Activated T cell therapy targeting glioblastoma cancer stem cells

  2023cites this paper
• Effective Dendritic Cell-based Immunotherapeutic Vaccines for Acute Myeloid Leukemia (AML)

  2014cites this paper
• Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells

  2014cites this paper
• Bifunctional Antibodies: Preclinical and Clinical Applications

  2014cites this paper
• Generation of lymphocytes potentiated against leukemic lymphoblasts by stimulation using leukemic cell lysate-pulsed dendritic cells in patients with acute lymphoblastic leukemia and measurement of in vitro anti-leukemic cytotoxicity

  2012cites this paper
• Anti-tumor immune responses in immune-reconstituted mice injected with a tumor vaccine

  2012cites this paper
• Role of the microenvironment in the tumourigenesis of microsatellite unstable and MUTYH-associated polyposis colorectal cancers.

  2012cites this paper
• DENDRITIC CELLS IN A MURINE MODEL OF BREAST CANCER: FUNCTIONAL AND PHENOTYPIC EVALUATION USING NANOPARTICLES

  2010cites this paper
• Cytotoxic T-cells as imaging probes for detecting glioma.

  2010cites this paper
• Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.

  2010cites this paper
• Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response

  2009cites this paper
• Cancer Immunotherapy and Aging: Lessons From the Mouse

  2009cites this paper
• Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.

  2009cites this paper
• Dendritic cell vaccines in acute leukaemia.

  2008cites this paper
• Current approaches in dendritic cell generation and future implications for cancer immunotherapy

  2007cites this paper
• Onconeural antibodies as a tool in the diagnosis of malignant tumors and paraneoplastic neurological syndromes

  2007cites this paper
• GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action

  2007cites this paper
• Myeloid disease Who to transplant with chronic myelocytic leukemia in the tyrosine kinase era

  year unknowncites this paper